Brain Research Bulletin, Год журнала: 2025, Номер unknown, С. 111237 - 111237
Опубликована: Янв. 1, 2025
Язык: Английский
Ageing Research Reviews, Год журнала: 2023, Номер 85, С. 101840 - 101840
Опубликована: Янв. 2, 2023
Язык: Английский
Процитировано
62
Expert Opinion on Pharmacotherapy, Год журнала: 2025, Номер unknown
Опубликована: Март 26, 2025
The past decade has seen a paradigm shift in the evaluation and management of Parkinson's disease psychosis (PDP), with first approval an antipsychotic US 2016. An evidence-based review by Movement Disorder Society found pimavanserin clozapine to be clinically useful, (low-dose) quetiapine possibly all other antipsychotics avoided due motor worsening. Clozapine use can limited provoking (PD) nonmotor symptoms somnolence hypotension. Quetiapine may also its risk cognitive impairment. Pimavanserin is not associated these symptoms. Despite advances understanding PDP US, clinical questions concerning patient selection, treatment timing, switch strategies, combination therapy remain. To develop consensus on first-line subsequent strategies for PDP, panel experts reviewed presentation course then discussed trial evidence experience. common but still undertreated sequela PD progression. recommended as based established safety efficacy. While switching are suggested, further study needed assess therapy.
Язык: Английский
Процитировано
2
International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(6), С. 5792 - 5792
Опубликована: Март 17, 2023
Parkinson’s disease is a neurodegenerative whose progression and clinical characteristics have close bidirectional multilevel relationship with the process of neuroinflammation. In this context, it necessary to understand mechanisms involved in neuroinflammation–PD link. This systematic search was, hereby, conducted focus on four levels where alterations associated neuroinflammation PD been described (genetic, cellular, histopathological clinical-behavioral) by consulting PubMed, Google Scholar, Scielo Redalyc engines, including studies, review articles, book chapters case studies. Initially, 585,772 articles were included, and, after applying inclusion exclusion criteria, 84 obtained that contained information about association gene, molecular, tissue neuroanatomical expression as well clinical-behavioral manifestations PD.
Язык: Английский
Процитировано
29
CNS Neuroscience & Therapeutics, Год журнала: 2024, Номер 30(2)
Опубликована: Фев. 1, 2024
The aim of this study is to investigate differences in gray matter volume and cortical complexity between Parkinson's disease with depression (PDD) patients without (PDND) patients.
Язык: Английский
Процитировано
10
Journal of Neural Transmission, Год журнала: 2022, Номер 129(12), С. 1397 - 1418
Опубликована: Ноя. 2, 2022
Язык: Английский
Процитировано
30
Neurological Sciences, Год журнала: 2023, Номер 44(5), С. 1607 - 1612
Опубликована: Янв. 18, 2023
Depression is one of the most disabling neuropsychiatric manifestations Parkinson's disease (PD) and requires proper screening diagnosis because it affects overall prognosis quality life patients. This study aimed to assess psychometric diagnostic properties Beck Inventory-II (BDI-II) in an Italian PD cohort.Fifty consecutive outpatients with underwent version BDI-II other questionnaires evaluate anxiety apathetic symptoms. Patients' caregivers completed depression/dysphoria domain Neuropsychiatric Inventory (NPI-D). We evaluated internal consistency, convergent divergent validity, factorial structure BDI-II. Sensitivity, specificity, positive negative predictive values, likelihood ratios were computed using ROC analyses, optimal cutoff was defined Youden index.The proved be internally consistent (Cronbach's α = 0.840) substantially met bi-factorial structure. Regarding construct related measures, but not apathy. With combination NPI-D score used as gold standard, showed good accuracy (AUC 0.859) adequate sensitivity (75%) specificity (87%). The point at 14.50.We provide evidence a tool for depression patients PD. found reliable valid measurement PD; therefore, available use clinical research practice.
Язык: Английский
Процитировано
23
Drug Delivery and Translational Research, Год журнала: 2023, Номер 14(2), С. 400 - 417
Опубликована: Авг. 19, 2023
Abstract Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder associated with increased oxidative stress, underlying vital process contributing to cell death. Tanshinone IIA (TAN) a phytomedicine documented activity in treating many CNS disorders, particularly PD owing its unique anti-inflammatory and antioxidant effect. However, clinical utility limited by poor aqueous solubility, short half-life, hence low concentration reaching targeted cells. This work aimed develop biocompatible chitosan-coated nanostructured lipid carriers (CS-NLCs) for effective brain delivery of TAN management. The proposed nanosystem was successfully prepared using simple melt-emulsification ultra-sonication method, optimized characterized both vitro vivo rotenone-induced rat model. developed TAN-loaded CS-NLCs (CS-TAN-NLCs) showed good colloidal properties (size ≤ 200 nm, PDI 0.2, ζ-potential + 20 mV) high drug entrapment efficiency (> 97%) sustained release profile 24 h. Following intranasal administration, CS-TAN-NLCs succeeded achieve remarkable antiparkinsonian antidepressant effect diseased animals compared uncoated TAN-NLCs free suspension as evidenced conducted behavioral tests improved histopathological findings. Furthermore, biochemical evaluation stress along inflammatory markers, nuclear factor-kabba β (NF-Kβ) cathepsin B further confirmed potential enhancing therapeutic treatment PD. Accordingly, could be addressed promising nano-platform management Graphical abstract
Язык: Английский
Процитировано
16
Medicina, Год журнала: 2023, Номер 59(8), С. 1454 - 1454
Опубликована: Авг. 12, 2023
Depression represents one of the most common non-motor disorders in Parkinson’s disease (PD) and it has been related to worse life quality, higher levels disability, cognitive impairment, thereby majorly affecting not only patients but also their caregivers. Available pharmacological therapeutic options for depression PD mainly include selective serotonin reuptake inhibitors, norepinephrine tricyclic antidepressants; meanwhile, agents acting on dopaminergic pathways used motor symptoms, such as levodopa, agonists, monoamine oxidase B (MAO-B) may provide beneficial antidepressant effects. Recently, there is a growing interest non-pharmacological interventions, including behavioral therapy; physical exercise, dance mind–body exercises, yoga, tai chi, qigong; acupuncture; massage; music active repetitive transcranial magnetic stimulation (rTMS); electroconvulsive therapy (ECT) refractory cases. However, optimal treatment approach uncertain, its management be challenging, definite guidelines are lacking. It still unclear which these interventions appropriate stage under circumstances. Herein, we aim an updated comprehensive review both treatments PD, focusing recent clinical trials, systematic reviews, meta-analyses. Finally, discuss that currently investigation at level, well future approaches based pathophysiological mechanisms underlying onset PD.
Язык: Английский
Процитировано
14
Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery), Год журнала: 2024, Номер 8, С. 982 - 991
Опубликована: Авг. 17, 2024
Parkinson's disease is a progressive neurodegenerative with motor symptoms and non-motor impairments, including depression, observed in 2.7-90% of cases. Depression frequently underestimated diagnosed late due to its similarity disease, such as fatigue, sleep disturbances, hypomimia, etc. In approximately 25% patients, depression precedes symptoms, which may indicate connection the pathogenesis disease. The purpose study was analyze current data on pathophysiology, diagnosis, treatment patients results have demonstrated that pathophysiological mechanisms include neurodegeneration dopaminergic, noradrenergic, serotonergic neurons, neuroinflammation, impaired neuroplasticity. For timely treatment, especially those changes or should be regularly examined. Treatment based multimodal approach includes use supportive psychotherapy pharmacotherapy. Alternative methods exercise, cognitive behavioral therapy, transcranial magnetic stimulation, electroconvulsive therapy are also being explored. Thus, requires an individualized approach. Further research into this problem crucial develop improve patient management algorithms.
Язык: Английский
Процитировано
6
Neurobiology of Disease, Год журнала: 2023, Номер 181, С. 106115 - 106115
Опубликована: Апрель 9, 2023
Parkinson's disease (PD) is a complex illness with constellation of environmental insults and genetic vulnerabilities being implicated. Strikingly, many studies only focus on the cardinal motor symptoms fail to appreciate major non-motor features which typically occur early in process are debilitating. Common comorbid psychiatric features, notably clinical depression, as well anxiety sleep disorders thought emerge before onset prominent deficits. In this review, we will delve into prodromal stage PD how neuropsychiatric pathology might unfold, followed by later disturbances. It also interest discuss animal models capture complexity illness, including depressive-like characteristics along impairment. remains be determined underlying processes contributes such comorbidity. But some toxicants microbial pathogens implicated instigate pro-inflammatory effects favoring α-synuclein accumulation damage brainstem neurons fueling evolution mood We posit that comprehensive animal-based research approaches needed time-dependent nature primary co-morbid symptoms. This allow for possibility intervention more novel targeted treatments fit not individual patient variability, but changes over time disease.
Язык: Английский
Процитировано
12